+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CHINA Genomic Biomarker Market 2019-2025

  • PDF Icon


  • January 2020
  • Region: China
  • Orion Market Research Private Limited
  • ID: 4988040
CHINA Genomic Biomarker Market Size, Share & Trends Analysis Report, By Application (Oncology, Cardiology, Neurology, and Others), By End-User (Hospitals and Diagnostic & Research Laboratories), and Forecast 2019-2025.

The genomic biomarker market in China is estimated to grow significantly at a CAGR of over 17% during the forecast period. China has emerged as a strong player in the biotechnology sector that results from the huge investments in R&D by the Chinese government. Chinese life science sector has progressively grown in the last years as a result of strong R&D and funding. The Chinese government has invested enormously in the cancer diagnostics making it a prominent region for the biomarker industry. China’s substantial patient populations in urban markets and research capability in genome sequencing have formed substantial opportunities for foreign companies. China has a clear market development priority for the IVD industry in the areas of cancer diagnostics, sequencing-based cancer assays, and companion diagnostics.

The genomic biomarker market is segmented on the basis of application and end-user. On the basis of application, the market is segmented into oncology, cardiology, neurology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. On the basis of end-user, the market is segmented into hospitals and diagnostic.

Some of the major players in the China genomic biomarker market include F. Hoffmann-La Roche Ltd., Pfizer Inc., Thermo Fisher Scientific Inc., Cancer Genetics Inc., BGI Group, and others. These companies are launching innovative products in the market, in order to meet the increasing demand for an effective diagnostic biomarker for cancer and cardiovascular diseases. Furthermore, the market players are adopting various strategies, in order to sustain in the competitive market, which includes partnership and collaboration, and investments. For instance, in March 2019, BGI Group planned to commercialize Natera’s Signatera molecular residual disease (MRD) test in China, and develop reproductive health tests in select markets on BGI's sequencing instruments, through a $50 million partnership announced by the two companies.

Research Methodology

The market study of the China genomic biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for healthcare companies, research institutes, hospitals, pharmaceutical, and biotechnology companies, potential investors and venture capitalists, government organizations, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis of the market size and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. China Genomic Biomarker Market Research and Analysis by Application
2. China Genomic Biomarker Market Research and Analysis by End-User

The Report Covers
  • Comprehensive research methodology of the China Genomic Biomarker Market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the China Genomic Biomarker Market.
  • Insights about market determinants which are stimulating the China Genomic Biomarker Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. China Genomic Biomarker Market by Application
5.1.1. Oncology
5.1.2. Cardiology
5.1.3. Neurology
5.1.4. Others
5.2. China Genomic Biomarker Market by End-User
5.2.1. Hospitals
5.2.2. Diagnostic & Research Laboratories
6. Company Profiles
6.1. Becton, Dickson, and Co.
6.2. BGI Group
6.3. Cancer Genetics, Inc.
6.4. Complete Genomics Inc.
6.5. Denovo Biopharma
6.6. Epigenomics AG
6.7. F-Hoffman-La Roche Ltd.
6.8. Ipsos Group
6.9. Novartis AG
6.10. Novogene Corp.
6.11. Pfizer, Inc.
6.12. Thermo Fisher Scientific Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Becton, Dickson, and Co.
  • BGI Group
  • Cancer Genetics, Inc.
  • Complete Genomics Inc.
  • Denovo Biopharma
  • Epigenomics AG
  • F-Hoffman-La Roche Ltd.
  • Ipsos Group
  • Novartis AG
  • Novogene Corp.
  • Pfizer, Inc.
  • Thermo Fisher Scientific Inc.